title: Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn.
abstract: Rapid evaluation of a neonate who is cyanotic and in respiratory distress is essential for achieving a good outcome. Persistent pulmonary hypertension of the newborn (PPHN) can be a primary cause or a contributing factor to respiratory failure, particularly in neonates born at 34 weeks or more of gestation. PPHN represents a failure of normal postnatal adaptation that occurs at birth in the pulmonary circulation. Rapid advances in therapy in recent years have led to a remarkable decrease in mortality for the affected infants. Infants who survive PPHN are at significant risk for long-term hearing and neurodevelopmental impairments, however. This review focuses on the diagnosis, recent advances in management, and recommendations for the long-term follow-up of infants who have PPHN.
authors.affiliation: Department of Pediatrics, Division of Neonatology, Children's Research Institute and Medical College of Wisconsin, Milwaukee, WI 53226, USA. gkonduri@mcw.edu
authors.forename: G Ganesh
authors.initials: GG
authors.lastname: Konduri
authors.forename: U Olivia
authors.initials: UO
authors.lastname: Kim
mesh_terms: D002316:Cardiotonic Agents / Q000627:therapeutic use; D000075202:Contraindications; D015199:Extracorporeal Membrane Oxygenation; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D015994:Incidence; D007231:Infant, Newborn; D008471:Meconium Aspiration Syndrome / Q000150:complications; D009569:Nitric Oxide / Q000627:therapeutic use; D010547:Persistent Fetal Circulation Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D012138:Respiratory Therapy / Q000379:methods*
chemical_list: D002316:Cardiotonic Agents; D006993:Hypnotics and Sedatives; D009569:Nitric Oxide